How COBENFY™ works

(xanomeline and trospium chloride)

Sagan is taking COBENFY and was compensated for his time.

Discover how COBENFY is different*

COBENFY was created with a different approach in mind by using a combination of two medicines, xanomeline and trospium chloride. Understand how this combination is thought to work by watching the video below.

Graphic with COBENFY logo, generic name, dosages, and tagline

COBENFY is the first and only FDA-approved schizophrenia medicine that is thought to work by activating small proteins in the brain called muscarinic acetylcholine receptors.

COBENFY is a unique combination of 2 medicines: xanomeline and trospium chloride

Xanomeline (Za-NO-muh-leen) is thought to activate muscarinic receptors in your brain to help adjust important chemical messengers related to your schizophrenia symptoms.

+

Trospium (TRO-spee-um) chloride may help prevent xanomeline from working outside your brain so that other parts of your body are less likely to be impacted.

The exact way that COBENFY works is not fully understood.

* A muscarinic agonist (xanomeline) and muscarinic antagonist (trospium chloride). The exact way that COBENFY works is not fully understood.

Bryan is taking COBENFY and was compensated for his time.



Cobenfy, Cobenfy Cares, and the Cobenfy logo are trademarks of Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
© 2026 Bristol-Myers Squibb Company.
1629-US-2600153 03/26
1629-US-2600035 01/26
This website is intended for U.S. residents 18 years of age or older.